BHI is proud to support ARPA-H through its Partnership Intermediary Agreement (PIA), providing EIR commercialization services to advance groundbreaking technologies. Notably, BaySpec, one of BHI’s clients, was awarded ARPA-H’s first SBIR grant to develop cutting-edge diagnostics. Andy Kilianski, Program Manager at ARPA-H, recaps key 2024 milestones, including AI-driven drug discovery, RNA therapies, and the $204M APECx biologics program. These efforts underscore ARPA-H’s commitment to accelerating biomedical innovation.
Portfolio Views from 2024
Andy Kilianski
Program Manager at ARPA-H
December 30, 2024
Happy Holidays Everyone!
2024 was a BIG year for my team and our investments in the biomedical and biotechnology ecosystem. Our goal is to invest in transformative technology that allows biomedical R&D to be predictive of human outcomes, in ways that are currently impossible. I want to capture some of our key milestones (in semi-chronological order) to highlight the amazing work already underway with our team at the Advanced Research Projects Agency for Health (ARPA-H) . My team and our performers have been incredibly diligent and dedicated to get us to this point. There are a lot of efforts soon-to-be-announced from us as we head into next year, including the kick-off of the CATALYST program mid-2025.
Site Visit to BaySpec Inc.
We are working with BaySpec Inc. to push the boundaries of point-of-care mass spectrometry methods. BaySpec has a history of innovation with government partners, including the Defense Advanced Research Projects Agency (DARPA), and we’re supporting their pivot from environmental sensing to medical diagnostics. The team is making progress on prototyping their MALDI-2 design with a disease-agnostic microbiology/pathology workflow. Testing to start soon! They also have the honor of being the first #SBIR award in ARPA-H history, which is very exciting.
Learning about the Future of Biotechnology and Health Innovation
My team is always learning, discovering, and engaging with leaders in all areas of biomedical innovation. One of the best parts of being a Program Manager at ARPA-H is the opportunity to step outside of my scientific comfort zone and scout for brilliant teams to work with in other research areas. This helps inform our program concept development and enables us to reach parts of industry and academia on the cutting edge. Two of these opportunities occurred early in the year and were critical for spreading word about the innovation happening at ARPA-H:
Read Andy’s full post at https://bit.ly/49YaSXU.